07:00 , May 30, 2016 |  BioCentury  |  Strategy

Taking Takeda global

Two years after joining Takeda Pharmaceutical Co. Ltd. , Christophe Weber has narrowed the company's therapeutic focus, expanded the executive team and reorganized its approach to market with the aim of transforming the company into...
07:00 , Oct 24, 2013 |  BC Innovations  |  Strategy

Synaptic synopsis

The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Now, genetic findings are pointing to new targets...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Clinical News

RG7203: Phase I started

Roche disclosed in its 2012 earnings that in 4Q12 it began a double-blind, placebo-controlled Phase I trial to evaluate single ascending-doses of RG7203 and a single dose of RG7203 in fed and fasted states in...
07:00 , May 20, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Schizophrenia Phosphodiesterase-10A (PDE-10A) In vitro and rat studies identified a class of PDE-10A inhibitors that could help treat schizophrenia. SAR studies identified imidazo[1,5-a]pyrido[3,2-e]pyrazine derivatives that...